Table 3.

Clinical response

First line chemotherapy (n = 303)
Complete response	9 (3.0 %)
Partial response	43 (14.2 %)
Stable disease	126 (41.6 %)
Disease control (CR + PR + SD)	178 (58.8 %)
Progression	99 (32.7 %)
Non evaluable	26 (8.5 %)
Second line chemotherapy (n = 162)
Complete response	1 (0.6 %)
Partial response	9 (5.4 %)
Stable disease	31 (18.6 %)
Disease control (CR + PR + SD)	41 (24.6 %)
Progression	78 (46.7 %)
Non evaluable	48 (28.7 %)
Third line chemotherapy (n = 56)
Complete response	0
Partial response	1 (1.8 %)
Stable disease	2 (3.6 %)
Disease control (CR + PR + SD)	3 (5.4 %)
Progression	27 (48.2 %)
Non evaluable	26 (46.4 %)